Amicus Therapeutics Inc (FOLD.OQ)
21 Mar 2018
Thu, Feb 15 2018
* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK
* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK
* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE
* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™
* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:
* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE
* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE
* Amicus therapeutics announces third quarter 2017 financial results and corporate updates
BELGRADE Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.
BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.
- Protalix: A Definite Sell - No Prize For The Fourth Runner Up
- Amicus Therapeutics (FOLD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
- Daily Insider Ratings Round Up 3/7/18: FOLD, ATT, CHN, EPD, GTE, CLR
- Daily Insider Ratings Roundup For March 6, 2018: FOLD, RDUS, BW, AXDX, TMUS, GKOS, And BOMN
- ROTY Volume 1 Edition 83: Thank You For Your Patience - Launch Day Has Arrived!
- Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2017 Results - Earnings Call Transcript